AbbVie Inc. (ABBV) FinancialsABBVFinancialAbbVie Inc.

AbbVie Inc. (ABBV) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Immunology-SKYRIZI, accounting for 32.4% of total sales, equivalent to $5.50B. Other significant revenue streams include Immunology-RINVOQ and Neuroscience-Vraylar. Understanding this composition is critical for investors evaluating how ABBV navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, AbbVie Inc. maintains a gross margin of 74.74%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 39.57%, while the net margin is 21.28%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ABBV converts its operational activities into shareholder value.

In the context of the broader market, ABBV competes directly with industry leaders such as MRK and ONC. With a market capitalization of $440.83B, it holds a leading position in the sector. When comparing efficiency, ABBV's gross margin of 74.74% stands against MRK's 47.07% and ONC's 89.76%. Such benchmarking helps identify whether AbbVie Inc. is trading at a premium or discount relative to its financial performance.

AbbVie has shown strong revenue growth, with Q2 2026 revenue reported at $16.99 billion and a gross margin of 74.74%. The net income for Q2 2026 was $3.61 billion, reflecting a solid recovery in profitability.